The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients

The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients
Conditions:   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
Sponsor:   Ohio State University Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 3, 2021Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments